GE Healthcare last week at the annual meeting of SNM in Salt Lake City, announced three pieces of radiopharmacy infrastructure—a cyclotron for large-scale radiotracer production, the expansion of its radiopharmacy chemistry synthesis portfolio and a PET radiotracer production infrastructure.
PETtrace 880 is the newest addition to the company’s PETtrace family of cyclotrons, allowing customers to establish, upgrade and operate their own research or clinical PET tracer production center, said GE.
The company also introduced TRACERlab FX E Pro, which provides the capability to produce 18F tracers via an “electrophilic” pathway for utilization in a hot lab. Associated with its 18F2 gas target, the PETtrace family can allow customers to produce tracers such as F-DOPA, F-Tyrosine or F-Uracil.
Also new is the TRACERcenter 710S, an upgradeable technology for customers establishing their infrastructure platform for radiotracer research, production or distribution. It produces tracers for oncology, offering customers tracer production possibilities with upgrade packages for neurology and cardiology, according to GE.